journal article·2024-12-03Open access

Assessing Therapeutic Nanoparticle Accumulation in Tumors Using Nanobubble-Based Contrast-Enhanced Ultrasound Imaging

Michaela B. Cooley, Dana Wegierak, Reshani Perera, Eric Abenojar, Pinunta Nittayacharn, Felipe M. Berg, Youjoung Kim, Michael C. Kolios, Agata A. Exner

ACS Nano· Volume 18· Issue 48

Abstract

High Resolution Image Download MS PowerPoint Slide This study explores the challenges associated with nanoparticle-based drug delivery to the tumor parenchyma, focusing on the widely utilized enhanced permeability and retention effect (EPR). While EPR has been a key strategy, its inconsistent clinical success lacks clear mechanistic understanding and is hindered by limited tools for studying relevant phenomena. This work introduces an approach that employs multiparametric dynamic contrast-enhanced ultrasound (CEUS) with a nanoscale contrast agent for noninvasive, real-time examination of tumor microenvironment characteristics. We demonstrate that CEUS imaging can: (1) evaluate tumor microenvironment features, (2) be used to help predict the distribution of doxorubicin-loaded liposomes in the tumor parenchyma, and (3) be used to predict nanotherapeutic efficacy. CEUS using nanobubbles (NBs) was carried out in two tumor types of high (LS174T) and low (U87) vascular permeability. LS174T tumors consistently showed significantly different time intensity curve (TIC) parameters, including area under the rising curve (AUC R, 2.7×) and time to peak intensity (TTP, 1.9×) compared to U87 tumors. Crucially, a recently developed decorrelation time (DT) parameter specific to NB CEUS dynamics successfully predicted the distribution of doxorubicin-loaded liposomes within the tumor parenchyma ( r = 0.86 ± 0.13). AUC R, TTP, and DT were used to correlate imaging findings to nanotherapeutic response with 100% accuracy in SKOV-3 tumors. These findings suggest that NB-CEUS parameters can effectively discern tumor vascular permeability, serving as a biomarker for identifying tumor characteristics and predicting the responsiveness to nanoparticle-based therapies. The observed differences between LS174T and U87 tumors and the accurate prediction of nanotherapeutic efficacy in SKOV-3 tumors indicate the potential utility of this method in predicting treatment efficacy and evaluating EPR in diseases characterized by pathologically permeable vasculature. Ultimately, this research contributes valuable insights into refining drug delivery strategies and assessing the broader applicability of EPR-based approaches.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Ultrasound and Hyperthermia Applications · Photoacoustic and Ultrasonic Imaging

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biomedical Engineering

Case Western Reserve University

Department of Radiology

Department of Biomedical Engineering, Faculty of Engineering

Mahidol University

Hospital Israelita Albert Einstein

Department of Physics

Toronto Metropolitan University

Institute for Biomedical Engineering, Science and Technology (iBEST), A Partnership between St. Michael’s Hospital

A Site of Unity Health Toronto and Toronto Metropolitan University

Funding

National Heart, Lung, and Blood Institute · National Institute of Biomedical Imaging and Bioengineering · National Institute of General Medical Sciences

References (100+)

Show source-provided references
1. Leading Causes of Death, 2022. https://wisqars.cdc.gov/lcd/?o=LCD&y1=&y2=2022&ct=10&cc=ALL&g=00&s=0&r=0&ry=2&e=0&ar=lcd1age&at=groups&ag=lcd1age&a1=0&a2=199. accessed October 17, 2024.
2. Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC) 2024. https://report.nih.gov/funding/categorical-spending#/. (accessed October 17, 2024).
3. 10.1002/btm2.1014310.1002/btm2.10143 ↗
4. 10.1038/nrc.2016.10810.1038/nrc.2016.108 ↗
5. 10.1038/s41565-019-0567-y10.1038/s41565-019-0567-y ↗
6. 10.1016/j.addr.2016.04.02510.1016/j.addr.2016.04.025 ↗
7. 10.1158/0008-5472.CAN-12-456110.1158/0008-5472.CAN-12-4561 ↗
8. 10.1016/j.phrs.2016.11.01410.1016/j.phrs.2016.11.014 ↗
9. 10.3390/cancers1412286810.3390/cancers14122868 ↗
10. 10.1021/acs.bioconjchem.6b0043710.1021/acs.bioconjchem.6b00437 ↗
11. 10.1158/1078-0432.CCR-16-199010.1158/1078-0432.CCR-16-1990 ↗
12. 10.1158/1078-0432.CCR-16-319310.1158/1078-0432.CCR-16-3193 ↗
13. 10.1021/acsnano.9b0971310.1021/acsnano.9b09713 ↗
14. 10.7150/thno.3828810.7150/thno.38288 ↗
15. 10.3892/mco.2014.35610.3892/mco.2014.356 ↗
16. 10.1038/nrc145610.1038/nrc1456 ↗
17. 10.1016/j.nano.2012.07.00210.1016/j.nano.2012.07.002 ↗
18. 10.1016/j.jconrel.2017.09.01510.1016/j.jconrel.2017.09.015 ↗
19. 10.1039/C5NR08463F10.1039/C5NR08463F ↗
20. 10.1016/j.jconrel.2018.04.02610.1016/j.jconrel.2018.04.026 ↗
21. 10.1016/j.addr.2017.07.00710.1016/j.addr.2017.07.007 ↗
22. 10.1016/j.jconrel.2022.09.00710.1016/j.jconrel.2022.09.007 ↗
23. 10.7150/thno.4590310.7150/thno.45903 ↗
24. 10.1016/j.jconrel.2013.08.29610.1016/j.jconrel.2013.08.296 ↗
25. 10.1158/1535-7163.MCT-15-031410.1158/1535-7163.MCT-15-0314 ↗
26. 10.1148/radiol.250208080110.1148/radiol.2502080801 ↗
27. 10.1007/s11307-017-1142-210.1007/s11307-017-1142-2 ↗
28. 10.20517/cdr.2020.9410.20517/cdr.2020.94 ↗
29. 10.7150/thno.3721510.7150/thno.37215 ↗
30. 10.1088/1361-6560/aae57210.1088/1361-6560/aae572 ↗
31. 10.1016/j.eml.2021.10136610.1016/j.eml.2021.101366 ↗
32. 10.1007/s00280-010-1305-110.1007/s00280-010-1305-1 ↗
33. 10.2967/jnumed.110.08399810.2967/jnumed.110.083998 ↗
34. 10.2147/IJN.S23917210.2147/IJN.S239172 ↗
35. 10.1016/j.jconrel.2018.05.00210.1016/j.jconrel.2018.05.002 ↗
36. 10.1016/j.ijrobp.2012.09.02710.1016/j.ijrobp.2012.09.027 ↗
37. 10.1002/wnan.195710.1002/wnan.1957 ↗
38. 10.1021/acsnano.7b0725210.1021/acsnano.7b07252 ↗
39. 10.1126/scitranslmed.aac652210.1126/scitranslmed.aac6522 ↗
40. 10.1158/1535-7163.MCT-19-070910.1158/1535-7163.MCT-19-0709 ↗
41. 10.7150/thno.2167010.7150/thno.21670 ↗
42. 10.1016/j.jconrel.2020.12.01410.1016/j.jconrel.2020.12.014 ↗
43. 10.1007/s00280-014-2477-x10.1007/s00280-014-2477-x ↗
44. 10.1002/advs.20210374510.1002/advs.202103745 ↗
45. 10.2967/jnumed.115.16617310.2967/jnumed.115.166173 ↗
46. 10.1021/acsnano.5b0132410.1021/acsnano.5b01324 ↗
47. 10.1038/ncomms1183810.1038/ncomms11838 ↗
48. 10.2147/IJN.S25474510.2147/IJN.S254745 ↗
49. 10.2214/AJR.12.922610.2214/AJR.12.9226 ↗
50. 10.4065/mcp.2010.026010.4065/mcp.2010.0260 ↗
51. 10.1088/0031-9155/60/21/R29710.1088/0031-9155/60/21/R297 ↗
52. 10.1371/journal.pone.021488710.1371/journal.pone.0214887 ↗
53. 10.1016/j.ejrad.2021.10960010.1016/j.ejrad.2021.109600 ↗
54. de Leon A. · 2018 · 139 · 57
55. 10.1016/j.cocis.2021.10146310.1016/j.cocis.2021.101463 ↗
56. Kreuter J. · J. Anat. · 1996 · 189 · 503
57. Pacheco-Blandino I. · 2012 · 42710.1533/9780857096357.427 ↗
58. 10.1016/j.biomaterials.2014.10.01310.1016/j.biomaterials.2014.10.013 ↗
59. 10.1088/1361-6528/ab704010.1088/1361-6528/ab7040 ↗
60. 10.1007/s00432-020-03160-710.1007/s00432-020-03160-7 ↗
61. 10.1016/j.biotechadv.2022.10809110.1016/j.biotechadv.2022.108091 ↗
62. 10.1021/acs.langmuir.2c0230310.1021/acs.langmuir.2c02303 ↗
63. 10.3389/fphar.2020.0036310.3389/fphar.2020.00363 ↗
64. 10.2147/IJN.S2883010.2147/IJN.S28830 ↗
65. 10.1117/1.330280810.1117/1.3302808 ↗
66. 10.1016/j.colsurfb.2015.03.02310.1016/j.colsurfb.2015.03.023 ↗
67. 10.3390/nano1307128310.3390/nano13071283 ↗
68. 10.1080/10717544.2021.202132110.1080/10717544.2021.2021321 ↗
69. 10.7150/thno.5131610.7150/thno.51316 ↗
70. 10.1021/acs.nanolett.0c0131010.1021/acs.nanolett.0c01310 ↗
71. Perera, R.; De Leon, A.; Wang, X. In Nanobubble Extravasation in Prostate Tumors Imaged with Ultrasound: Role of Active versus Passive Targeting , IEEE International Ultrasonics Symposium (IUS); IEEE, 2018.10.1109/ULTSYM.2018.8580221 ↗
72. 10.1016/j.nano.2016.08.02010.1016/j.nano.2016.08.020 ↗
73. 10.1016/j.ultrasmedbio.2019.05.02510.1016/j.ultrasmedbio.2019.05.025 ↗
74. 10.1038/s41598-021-84072-510.1038/s41598-021-84072-5 ↗
75. 10.1073/pnas.95.8.460710.1073/pnas.95.8.4607 ↗
76. Yuan F. · Cancer Res. · 1994 · 54 · 3352
77. 10.1038/s41565-023-01323-410.1038/s41565-023-01323-4 ↗
78. 10.3389/fonc.2021.69265010.3389/fonc.2021.692650 ↗
79. Leunig M. · Cancer Res. · 1992 · 52 · 6553
80. 10.1593/neo.12114810.1593/neo.121148 ↗
81. 10.1016/j.ejrad.2018.05.01310.1016/j.ejrad.2018.05.013 ↗
82. 10.1016/j.bioactmat.2022.05.00110.1016/j.bioactmat.2022.05.001 ↗
83. 10.1039/D3LC00514C10.1039/D3LC00514C ↗
84. 10.1109/TMI.2024.336407610.1109/TMI.2024.3364076 ↗
85. 10.2147/HP.S13323110.2147/HP.S133231 ↗
86. 10.1155/2013/89814610.1155/2013/898146 ↗
87. 10.1002/mp.1596210.1002/mp.15962 ↗
88. 10.7150/ntno.6473510.7150/ntno.64735 ↗
89. Lee C. G. · Cancer Res. · 2000 · 60 · 5565
90. Netti P. A. · Cancer Res. · 2000 · 60 · 2497
91. 10.1002/cam4.162410.1002/cam4.1624 ↗
92. 10.1055/s-0030-125345410.1055/s-0030-1253454 ↗
93. 10.1117/1.JBO.28.7.07600110.1117/1.JBO.28.7.076001 ↗
94. 10.1016/j.ctrv.2010.05.00110.1016/j.ctrv.2010.05.001 ↗
95. 10.1038/ncomms1068410.1038/ncomms10684 ↗
96. 10.3109/03009734.2015.106450110.3109/03009734.2015.1064501 ↗
97. 10.1039/C9NR04828F10.1039/C9NR04828F ↗
98. 10.1016/j.nano.2020.10221310.1016/j.nano.2020.102213 ↗
99. 10.1109/58.89613610.1109/58.896136 ↗
100. 10.1039/D0NR05390B10.1039/D0NR05390B ↗